Logo

AST/IDSA Webinar: COVID-19 Vaccine in Transplant & Immunocompromised Populations - Shared screen with speaker view
Deirdre Lewis
45:35
https://www.myast.org/covid-19-vaccine-faq-sheet
Rajesh Gandhi
56:33
What is the rate of Ab positivity using these assays after 1 dose of m
Rajesh Gandhi
56:54
RNA vaccine in non-transplant patients?
Dana Wollins
57:05
Please use the Q&A box to ask your question.
Joud Jarrah
01:13:29
I have a BMT patient presneted with graft, liver and kidney failure, 2 weeks post first dose of Moderna vaccine. We can't prove causation for sure, my question, when to reconsider the second dose, knowing the the Moderna vaccine is dosed higher than Pfizer vaccine? Thank you
Dana Wollins
01:16:15
Please ask your question using the Q&A box.
Deirdre Lewis
01:27:01
AST Resources:https://www.myast.org/covid-19-vaccine-faq-sheethttps://www.myast.org/covid-19-informationCOVID-19 Real-Time Learning Network:www.COVID19LearningNetwork.orgVaccine FAQ:https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines-information--faq/@RealTimeCOVID19#RealTimeCOVID19
Judith M. Harris, LCSW
01:27:08
Thank you all! Excellent presentation.
Deirdre Lewis
01:27:59
ASCO/IDSA Global Webinar: COVID-19 Vaccines and Cancer CareTo Register: https://asco1.zoom.us/webinar/register/WN_B5a0zz4JR1yqdb4zseu6jARecordings of this call will be posted on:www.idsociety.org/cliniciancallswww.myAST.org/covid